BMC Pulmonary Medicine最新文献

{"title":"Postoperative symptom network analysis in non-small cell lung cancer patients: a cross-sectional study.","authors":"Sha Zhang, Yao Deng, Xiaorun Xiang, Qianfeng Xu, Lixin Hu, Mei Xia, Lei Liu","doi":"10.1186/s12890-025-03711-z","DOIUrl":"10.1186/s12890-025-03711-z","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the incidence and severity of symptoms in postoperative non-small-cell lung cancer patients undergoing thoracoscopic surgery, construct a symptom network, and analyze centrality indicators of the network to identify core symptoms and provide a basis for precise symptom management.</p><p><strong>Methods: </strong>A convenience sampling method was used to select postoperative NSCLC patients from the Department of Thoracic Surgery at the First Affiliated Hospital of Army Medical University between September 2024 and December 2024. The Chinese version of the Anderson Symptom Inventory Core Symptom Module and the revised Lung Cancer-Specific Symptom Module were used to survey the incidence and severity of symptoms. A symptom network was constructed with R software with the EBICgloss function and Spearman correlation analysis, and the centrality indicators were then calculated.</p><p><strong>Results: </strong>In total, 404 questionnaires were distributed, and 367 valid questionnaires were returned (effective response rate, 90.8%). The top three symptoms in terms of incidence and severity during the postoperative hospitalization of NSCLC patients were pain (100%), fatigue (99%), and shortness of breath (98%). The results of the centrality indicators of the symptom network revealed that the top three symptoms in terms of strength centrality were shortness of breath (rs = 5.44), fatigue (rs = 5.43), and pain (rs = 5.34).</p><p><strong>Conclusion: </strong>Postoperative NSCLC patients experience various symptoms, with shortness of breath being the core symptom. Targeted intervention strategies are needed to improve the efficiency and accuracy of symptom management, reduce the symptom burden on patients, and increase their quality of life.</p><p><strong>Clinical trial registration: </strong>Chinese Clinical Trial Registry (NO. ChiCTR2500096720), registered on 5 February 2025, retrospectively registered.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"244"},"PeriodicalIF":2.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARID1A silencing-mediated upregulation of microRNA-652 accelerates cigarette smoke-induced human bronchial epithelial cell transformation by targeting ZFAND5.","authors":"Kang-Liang Zhang, Dan-Ni Wu, Rui-Heng Chen, Chong Zheng, Ri-Sheng Huang, Xiao-Dan Zhao","doi":"10.1186/s12890-025-03718-6","DOIUrl":"10.1186/s12890-025-03718-6","url":null,"abstract":"<p><p>Cigarette smoking is an important risk factor in lung cancer development. As a class of regulatory RNAs, microRNAs (miRs) participate in various biological processes. In the present study, we searched for the key miRs that mediate cigarette smoke-induced aggressive phenotype in human bronchial epithelial (HBE) cells. Our results demonstrated that miR-652 was upregulated in cigarette smoke extract (CSE)-exposed HBE cells. ARID1A silencing due to hypermethylation of its promoter accounted for the upregulation of miR-652 in CSE-treated HBE cells. Overexpression of miR-652 accelerated the proliferation, migration, and anchorage-independent growth of HBE cells exposed to CSE. Knockdown of miR-652 attenuated the growth and migration of CSE-treated HBE cells. According to bioinformatic prediction and luciferase reporter assays, ZFAND5 was found to be a target of miR-652. Overexpression of miR-652 suppressed the protein expression of ZFAND5 in HBE cells, without altering its mRNA abundance. CSE treatment reduced the protein expression of ZFAND5 in HBE cells. Depletion of ZFAND5 potentiated the anchorage-independent growth and migration of CSE-treated HBE cells. Enforced expression of ZFAND5 reversed miR-652-mediated enhancement of anchorage-independent growth and migration in CSE-treated HBE cells. In conclusion, miR-652 potentiates CSE-induced aggressive phenotype in HBE cells by repressing ZFAND5 protein expression. The potential involvement of miR-652 in cigarette smoking-related lung carcinogenesis warrants further investigation.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"245"},"PeriodicalIF":2.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of initial empirical antibiotic regimens in severe community-acquired pneumonia: a network meta-analysis.","authors":"Min Wang, Jing Zhang, Xiaoming Wang, Qian Wang, Lian Wang, Han Zhuang, Ao Liu","doi":"10.1186/s12890-025-03695-w","DOIUrl":"10.1186/s12890-025-03695-w","url":null,"abstract":"<p><strong>Background: </strong>Severe community-acquired pneumonia (SCAP) remains a leading cause of morbidity and mortality worldwide. Identifying the optimal antibiotic regimen for treating SCAP is crucial for improving patient outcomes.</p><p><strong>Methods: </strong>We searched the PubMed, Embase, and Cochrane Central Register of Controlled Clinical Trials databases to identify studies reporting initial empirical antibiotic regimens in patients with SCAP. We performed a network meta-analysis to compare the relative efficacy of different antibiotic regimens in treating SCAP. The primary outcome was overall mortality. The second outcomes were 30-day mortality and in-hospital mortality.</p><p><strong>Results: </strong>This network meta-analysis included 1 randomized clinical trial and 13 observational studies with 8142 patients, categorized into five treatment groups: β-lactam antibiotics, β-lactam antibiotics plus doxycycline, β-lactam antibiotics plus fluoroquinolones, β-lactam antibiotics plus macrolides, and fluoroquinolones monotherapy. β-lactam antibiotics plus macrolides was ranked as the most effective treatment (surface under the cumulative ranking curve, 92.0%; mean rank, 1.3). The β-lactam antibiotics plus macrolides combination significantly reduced overall mortality compared to β-lactam antibiotics alone (RR, 0.79; 95% CI, 0.64-0.96) and β-lactam antibiotics plus fluoroquinolones (RR, 0.67; 95% CI, 0.64-0.82).</p><p><strong>Conclusion: </strong>Our findings suggest that β-lactam antibiotics plus macrolides may be the optimal treatment for SCAP. β-lactam antibiotics monotherapy and β-lactam antibiotics plus fluoroquinolones should not be recommended due to their inferior outcomes.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"246"},"PeriodicalIF":2.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of EOS count and serum VEGF in bronchial asthma and their correlation with inflammatory factors and lung function indicators.","authors":"Longqun Liu, Chenfei Zhang, Jian Xu, Wei Hu","doi":"10.1186/s12890-025-03485-4","DOIUrl":"10.1186/s12890-025-03485-4","url":null,"abstract":"<p><strong>Objective: </strong>To probe the diagnostic value of direct eosinophils (EOS) count and vascular endothelial growth factor (VEGF) in bronchial asthma (BA) and their correlation with inflammatory factors and lung function indicators.</p><p><strong>Methods: </strong>A total of 66 patients with BA (BA group) were retrospectively gathered, who were further divided into mild (n = 25), moderate (n = 31), and severe (n = 10) subgroups based on asthma severity. Additionally, 60 healthy individuals undergoing physical examinations during the same period were enrolled as the normal group. The EOS count, serum VEGF, inflammatory factors [interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-10 (IL-10)], and lung function indicators [forced expiratory volume in one second (FEV1%) as a percentage of the predicted value, FEV1/forced vital capacity (FVC)] were compared among different groups. Spearman correlation analysis was performed to assess the correlation between EOS count, serum VEGF, and inflammatory factors, as well as lung function indicators in the BA group. Receiver operating characteristic (ROC) curves and Delong's test were adopted to analyze the diagnostic value of EOS and VEGF individually and in combination for BA and the severity of BA.</p><p><strong>Results: </strong>Versus the normal group, the BA group exhibited higher EOS count and serum levels of VEGF, IL-6, and IL-7, but lower levels of IL-10, FEV1%, and FEV1/FVC. In the severe subgroup, EOS count and serum VEGF, IL-6, and IL-7 levels were higher than those in the moderate and mild subgroups, while the moderate subgroup had higher values than the mild subgroup. IL-10, FEV1%, and FEV1/FVC were lower in the severe subgroup versus the moderate and mild subgroups, and the moderate subgroup had lower levels than the mild subgroup (all p < 0.05). Spearman correlation analysis unveiled positive correlations between EOS count and VEGF with IL-6 and IL-7 (r > 0, p < 0.05), but negative correlations with IL-10, FEV1%, and FEV1/FVC (r < 0, p < 0.05). ROC curve analysis displayed that the areas under the curve (AUCs) for EOS count and serum VEGF individually in diagnosing BA were 0.767 and 0.807. The AUC for the combined diagnosis of both (0.875) was significantly greater than the AUC for each test used alone (p < 0.05). The AUC for using EOS count alone to diagnose the severity of BA in patients was 0.936, while the AUC for using serum VEGF alone was 0.963. The AUC for the combined diagnosis of both (1.000) was significantly greater than the AUC for EOS count alone (p < 0.05).</p><p><strong>Conclusion: </strong>There is a correlation between EOS count, serum VEGF, inflammatory levels, and lung function indicators in patients with BA. The combined detection of EOS count and serum VEGF levels has guiding significance for clinical diagnosis and disease assessment.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"242"},"PeriodicalIF":2.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nomogram-based clinical prediction model for adverse clinical outcomes in non-HIV Pneumocystis jirovecii pneumonia patients.","authors":"Dong Wang, Lujia Guan, Qian Yin, Xiaoxia Hou, Xi Zhan, Zhaohui Tong","doi":"10.1186/s12890-025-03700-2","DOIUrl":"10.1186/s12890-025-03700-2","url":null,"abstract":"<p><strong>Background: </strong>Non-human immunodeficiency virus (HIV) immunocompromised patients with Pneumocystis jirovecii pneumonia (PJP) face rapid progression and high mortality, necessitating a predictive model to identify patients at risk of adverse clinical outcomes for timely interventions and improved stratification.</p><p><strong>Methods: </strong>Patients admitted between January 2011 and June 2024 at Beijing Chao-Yang Hospital were retrospectively analyzed. Collected data included patients' demographics, smoking status, comorbidities, immunosuppressive diseases, blood laboratory tests, in-hospital treatment, and adverse clinical outcomes. Predictor selection was performed using the least absolute shrinkage and selection operator (LASSO) and logistic regression, with selected features incorporated into a nomogram. Internal validation was conducted using a 500-bootstrap resampling method to ensure model robustness. Model performance was assessed via the area under the receiver operating curve (AUC), calibration plots, decision curve analysis (DCA), and clinical impact curve (CIC).</p><p><strong>Results: </strong>Among the 431 patients, 243 (56.4%) experienced adverse clinical outcomes. LASSO regression screened 21 variables, selecting 9 predictors with non-zero coefficients through 10-fold cross-validation at lambda.1se = 0.0453 (log(lambda.1se) = -3.092). Multivariate logistic regression identified 7 independent risk factors for adverse clinical outcomes: smoking status, cytomegalovirus infection, diabetes, neutrophil-lymphocyte ratio (NLR), lactate dehydrogenase (LDH), PaO₂/FiO₂ (PFR), and lymphocyte subset. These factors were incorporated into a nomogram, achieving an AUC of 0.89 (95% CI: 0.86-0.92), with the Hosmer-Lemeshow test (p = 0.134) and calibration curves showing strong agreement between predicted and observed outcomes. Internal validation via 500-bootstrap resampling yielded a bias-corrected AUC of 0.83 (95% CI: 0.80-0.86). DCA demonstrated strong clinical decision-making utility, while the CIC confirmed its practical reliability.</p><p><strong>Conclusions: </strong>Regression analysis identified smoking status, CMV infection, diabetes, NLR, LDH, PFR, and lymphocyte subset as independent risk factors for adverse clinical outcomes in non-HIV PJP patients. The predictive model constructed from these factors exhibited robust accuracy and reliability.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"238"},"PeriodicalIF":2.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of adding a peak flow meter for the identification of patients with chronic obstructive pulmonary disease in real-world clinical practice.","authors":"Hideki Ikeda","doi":"10.1186/s12890-025-03708-8","DOIUrl":"10.1186/s12890-025-03708-8","url":null,"abstract":"<p><p>Peak expiratory flow (PEF) measurement is useful for detecting moderate and severe chronic obstructive pulmonary disease (COPD). We aimed to validate its combined effectiveness with a questionnaire and to determine appropriate cutoff values in Japan. Outpatients aged ≥ 60 years with a smoking index ≥ 400 cigarette-years receiving non-respiratory treatment and patients with COPD receiving regular treatment underwent PEF measurements and pulmonary function tests. Receiver operating characteristic (ROC) curves were created to differentiate between the percentage forced expiratory volume in 1 s (%FEV₁) values above or below 80%, based on PEF values normalized by height (method A) and height squared (method B). Of 98 patients, COPD was confirmed in 15 (15.3%). The reference values used to estimate %FEV₁ < 80% derived from the ROC curve were 2.40 and 1.37 for methods A and B, respectively. Both methods had a high area under the ROC curve (0.92) (p < 0.001). The number of suspected COPD (sCOPD) cases was narrowed down from 98 to 33 and 27 using methods A and B, respectively. The combination of the COPD questionnaire and peak flow meter can effectively differentiate severe from the more severe half of moderate COPD from sCOPD cases and improve diagnosis of asymptomatic COPD cases that may require medication prescription by general practitioners.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"239"},"PeriodicalIF":2.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphatic malformations involving the thorax in children: a retrospective cohort study.","authors":"Wenting Han, Haiming Yang, Jinrong Liu, Huimin Li, Hui Xu, Hui Liu, Xiaolei Tang, Shunying Zhao","doi":"10.1186/s12890-025-03723-9","DOIUrl":"10.1186/s12890-025-03723-9","url":null,"abstract":"<p><strong>Background: </strong>Lymphatic malformations (LMs) involving the thorax are rare, with limited clinical understanding. We aimed to summarize the classification, clinical features, treatment, and prognosis of thoracic LMs, and to improve disease management and patient outcomes.</p><p><strong>Methods: </strong>Clinical data and follow-up data obtained from 42 patients with thoracic LMs were reviewed retrospectively at a single center in China.</p><p><strong>Results: </strong>Patients were classified into 7 types: 1 with macrocystic LM, 3 with infancy primary chylothorax, 4 with primary lymphedema (PL), and 34 with complicated lymphatic anomalies (CLAs), including 18 with generalized lymphatic anomaly (GLA), 8 with kaposiform lymphangiomatosis (KLA), 6 with central conducting lymphatic anomaly (CCLA), and 2 with Gorham-Stout disease. The specific clinical manifestations included chylothorax (50%), white foamy/jelly-like sputum (47.6%), and plastic bronchitis (7.1%). Imaging findings revealed interlobular septal thickening in 20 patients (47.6%) and ground-glass opacity in 13 (31.0%). Improvements were observed in 16 patients with CLAs who were administered sirolimus, 2 with GLA who were administered sirolimus and bevacizumab, 1 with KLA who was administered trametinib, 6 with CCLA who underwent surgery, 3 with infancy primary chylothorax following dietary treatment, and 1 with macrocystic LM following sclerotherapy. Stabilization occurred in 7 patients (3 with CLAs and 4 with PL) postsurgery. Progression or death was observed in 4 patients with GLA and 3 patients with KLA.</p><p><strong>Conclusions: </strong>Different types of thoracic LMs have similar clinical features and imaging manifestations but vary in terms of treatment and prognosis.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"241"},"PeriodicalIF":2.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of a systematic multi-dimensional assessment in severe uncontrolled asthma: a literature review and protocol for an investigator-initiated, open-label, randomized-controlled trial (EXACT@home study).","authors":"L Bult, G J Braunstahl, J G J V Aerts, D Bänffer, J S J A van Campen, M S van Daalen, Y van Dooren, U Flanders, E S Geurts, P P Hekking, R Heller-Baan, M J A Jans, J H Kappen, R C A Mies, B Oppedijk, M de la Roij-Hartmans, S Van der Sar-Van der Brugge, Y Türk, E Vis, R Wolters, E C Vasbinder, J C C M In 't Veen","doi":"10.1186/s12890-025-03646-5","DOIUrl":"10.1186/s12890-025-03646-5","url":null,"abstract":"<p><strong>Introduction: </strong>Severe asthma affects 3.6% of the asthma population, in which patients are uncontrolled despite optimal drug therapy and management of treatable traits. These patients are eligible for treatment with biologicals, which provide significant benefits but are costly and need precise indication. However, identifying all individual treatable traits before diagnosing severe asthma is challenging. A systematic multi-dimensional assessment may help identify and address these hidden traits, resulting in tailored treatment and reducing the number of unnecessary biological prescriptions.</p><p><strong>Methods: </strong>A literature review was conducted to address the knowledge gap on the effectiveness and added value of a systematic assessment and treatment in difficult-to-treat or severe asthma, followed by an outline of a study protocol to implement this in patients diagnosed with severe asthma.</p><p><strong>Results: </strong>The literature review revealed limited evidence on the effectiveness of systematic assessments in difficult-to-treat or severe asthma, largely due to the use of different study methods and outcome measures. Notably, only one of the selected articles employed a randomized controlled design. To address this gap, the EXpert Asthma Copd Trajectory with digital support (EXACT@home) study was proposed, which aims to improve the assessment and treatment of treatable traits in severe asthma before (re)considering treatment with biologicals. This study uses a prospective, open label, randomized controlled trial design with the primary aim of reducing biological prescriptions. Patients are eligible for inclusion if they have previously been diagnosed with severe uncontrolled asthma with an indication for treatment with biologicals. The intervention arm undergoes a 6-week systematic assessment program targeting treatable traits followed by tailored treatment, while the control arm directly receives treatment with biologicals. Both arms are followed for 12 months with secondary outcomes including asthma control, quality of life and exacerbation frequency.</p><p><strong>Discussion: </strong>Difficult-to-treat or severe asthma requires tailored treatments based on individual treatable traits, but challenges remain in accurately identifying these traits. Existing literature highlights the beneficial effects of systematic assessments, but conclusive evidence is lacking. The EXACT@home study aims to provide high quality evidence on the effectiveness of such an assessment in the management of severe uncontrolled asthma, addressing a gap in the current literature.</p><p><strong>Trial registration: </strong>NCT05831566 (Clinicaltrials.gov), registered at 14-04-2023.</p><p><strong>Protocol version: </strong>version 6, date 27-03-2024.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"240"},"PeriodicalIF":2.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival analysis of patients with pneumoconiosis followed in occupational medicine clinics: 10 years experience.","authors":"Melike Yüksel Yavuz, Ayşe Coşkun Beyan, Merve Ayik Türk, Türkan Dizdar Canbaz, Ö Melis Korkmaz Özgüngör, Nur Şafak Alici","doi":"10.1186/s12890-025-03676-z","DOIUrl":"10.1186/s12890-025-03676-z","url":null,"abstract":"<p><strong>Background: </strong>Pneumoconiosis is still the most common occupational disease worldwide. The aim of the study was to evaluate the risk factors affecting survival in patients with pneumoconiosis who were followed up in occupational medicine clinics.</p><p><strong>Methods: </strong>This retrospective descriptive study included all pneumoconiosis patients followed up in occupational medicine clinics between 2013 and 2023. The patients' death records were accessed through the national death notification system.</p><p><strong>Results: </strong>A total of 539 patients were included in the study. During the clinical follow-up, 14 (2.56%) patients had died. The mean overall survival time was 224 ± 13 months. In multiple analyses, silica exposure (p = 0.029) and lung cancer development (p = 0.002) were associated with survival. There was no difference between stages 0 and 1, stage 2 and stage 3 in terms of age at diagnosis, type of disease and duration of dust exposure (respectively p = 0.109, p = 0.852).</p><p><strong>Conclusions: </strong>This study showed that exposure to silica as a dust type and the development of lung cancer increased mortality in patients with pneumoconiosis. Determining the factors that may be associated with mortality in patients with pneumoconiosis is important in patient follow-up and in developing preventive measures and policies. It is crucial that the establishment of lung cancer screening programs contribute to life expectancy.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"236"},"PeriodicalIF":2.6,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring COPD patients systemic and bronchial eosinophilic inflammation in a 2-year follow-up: few concerns.","authors":"Divya Balan, Mohan K Manu","doi":"10.1186/s12890-025-03717-7","DOIUrl":"10.1186/s12890-025-03717-7","url":null,"abstract":"<p><p>Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up\" by Pignatti et al. provides valuable insights about changes in blood and sputum eosinophils in mild to moderate COPD patients and treatment outcomes. However, concerns arise regarding the accuracy of diagnosis of COPD in subjects with a significant bronchodilator response despite FEV1/FVC ≤ 70%. Although statistically significant differences in FEV1/FVC were observed, the clinical relevance needs scrutiny. Despite a clinically meaningful difference in FEV1 between ICS-treated and untreated patients, the lack of statistical significance raises questions. Addressing these concerns will strengthen the study's reliability and interpretation.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"235"},"PeriodicalIF":2.6,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}